COVID-19 Vaccination Economic Benefits by Age Group
- New research published in JAMA Network Open demonstrates that broad COVID-19 vaccination isn't just a public health imperative-it's a financially sound one.
- The study utilized a complex computer model to assess the economic impact of vaccination across different age groups: 18-49, 50-64, and 65+.
- A "quality-adjusted life year" (QALY) is a measure of health outcome that combines both the quantity and quality of life.
COVID-19 Vaccination: A Sound Investment in Health and Economy
Table of Contents
Updated August 18, 2025
The Economic Case for Vaccination
New research published in JAMA Network Open demonstrates that broad COVID-19 vaccination isn’t just a public health imperative-it’s a financially sound one. A collaborative study by researchers at the University of Michigan (U-M) and the Centers for Disease Control and Prevention (CDC) projects significant economic savings resulting from reduced severe illness, hospitalizations, deaths, and lost productivity. The findings underscore the value of continued vaccination efforts as the virus continues to evolve.
Age-Specific Cost-Effectiveness
The study utilized a complex computer model to assess the economic impact of vaccination across different age groups: 18-49, 50-64, and 65+. The results revealed a clear trend: the older the demographic, the greater the economic benefit of vaccination.
Key Findings by Age Group:
| Age Group | Cost-Effectiveness | Hospitalizations Averted (per 100,000 vaccinated) | Deaths Averted (per 100,000 vaccinated) |
|---|---|---|---|
| 65+ | Cost-Saving | 391 | 43 |
| 50-64 | $25,787 per QALY gained | N/A | N/A |
| 18-49 | $115,588 per QALY gained (under specific conditions) | N/A | N/A |
A “quality-adjusted life year” (QALY) is a measure of health outcome that combines both the quantity and quality of life. An ICER (incremental cost-effectiveness ratio) below $50,000 is generally considered cost-effective.
Single vs. Multiple Doses: A Nuanced Approach
The research indicated that a single dose of the updated 2023-2024 mRNA COVID-19 vaccine provides substantial protection and economic benefit across all age groups.However,the economic advantage of a second dose varied. For adults aged 65 and older, a second dose remained economically favorable, particularly for those at higher risk. Interestingly, for non-immunocompromised adults under 64, a second dose did not demonstrate a positive economic return, aligning with current CDC recommendations.
Study limitations and Future Research
Researchers acknowledge certain limitations to the study. The analysis relied on unpublished data and initial hospitalization data didn’t differentiate between patients hospitalized *because* of COVID-19 and those with incidental COVID-19 infections. Furthermore, the model didn’t account for the potential impact of vaccination on reducing overall virus transmission. However, the authors note that if vaccination *does* significantly reduce transmission, the economic benefits would likely be even greater.